Expanding BCG-primed Antigen Presenting Cells to Novel Therapeutic Applications

This inventive concept leverages the core technology of BCG-primed antigen presenting cells to treat a range of diseases beyond bladder cancer, including autoimmune disorders, graft rejection, neurological disorders, and enhancing immune response to vaccines.

The original patent focused on treating bladder cancer using BCG-primed antigen presenting cells. However, this technology has broader potential. Current treatments for autoimmune disorders, graft rejection, and neurological disorders often have limited efficacy or significant side effects. This inventive concept addresses these limitations by applying the core technology to these new applications, providing a more targeted and effective approach.

The new claims describe systems, methods, and devices for treating autoimmune disorders, preventing graft rejection, and treating neurological disorders using BCG-primed antigen presenting cells. These cells are isolated from subjects treated with Bacillus Calmette-Guerin (BCG) and cultured with IL-15 based superagonists. The inventive concept involves administering these cells to subjects in need, using devices and systems designed for efficient delivery and monitoring. The composition and administration of the antigen presenting cells are critical components, as they enable targeted immune responses and improved treatment outcomes.

The new claims introduce novel applications and use cases for the core technology, expanding its scope beyond bladder cancer. The inventive step lies in recognizing the potential of BCG-primed antigen presenting cells to address unmet needs in autoimmune disorders, graft rejection, and neurological disorders, and developing systems, methods, and devices to realize this potential.

Alternative embodiments could include modifying the composition of the antigen presenting cells, adjusting the dosage and administration protocols, or incorporating additional therapeutic agents to enhance treatment outcomes. Variations may also involve using different sources of antigen presenting cells or alternative IL-15 based superagonists.

The inventive concept has significant commercial potential in the fields of autoimmune disorders, organ transplantation, and neurological disorders. The market for these applications is substantial, with millions of people worldwide affected by these conditions. The inventive concept offers a promising solution with potential for significant revenue growth and improved patient outcomes.